https://www.yiliao.com/index.php?action=history&feed=atom&title=%E4%BD%90%E5%8D%9A%E5%A6%A5%E7%8F%A0%E5%8D%95%E6%8A%97
佐博妥珠单抗 - 版本历史
2026-04-19T22:28:15Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E4%BD%90%E5%8D%9A%E5%A6%A5%E7%8F%A0%E5%8D%95%E6%8A%97&diff=313300&oldid=prev
223.160.138.166：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-06T07:19:19Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[佐博妥珠单抗]]([[Zolbetuximab]])</strong>，商品名为<strong>[[维妥妥]]([[Vyloy]])</strong>，研发代码为<strong>[[IMAB362]]</strong>，是由<strong>[[安斯泰来]]([[Astellas]])</strong>研发的一种首创（[[First-in-class]]）人鼠嵌合单克隆抗体。它是全球首个获批上市靶向<strong>[[Claudin18.2]]([[CLDN18.2]])</strong>的药物。在2026年的肿瘤临床路径中，[[佐博妥珠单抗]]联合化疗已成为<strong>[[HER2阴性]]</strong>、[[CLDN18.2]]高表达的局部晚期或转移性<strong>[[胃腺癌]]</strong>及<strong>[[胃食管结合部腺癌]]</strong>的一线标准治疗方案，标志着胃癌精准治疗正式迈入“后HER2”时代。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">佐博妥珠单抗</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Zolbetuximab (Vyloy)·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Zolbetuximab-CLDN18.2 Binding Interaction Model</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶标：[[CLDN18.2]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">51220</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]编号</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2043</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P56856</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约148kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发公司</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[安斯泰来]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">给药方式</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">静脉滴注 (Q2W/Q3W)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026状态</th><br />
<td style="padding: 12px; color: #1e40af;">全球首个CLDN18.2靶向药</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：选择性靶向与免疫介导杀伤</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[佐博妥珠单抗]]通过高特异性地结合肿瘤细胞表面的[[CLDN18.2]]蛋白发挥抗肿瘤作用。<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>高度靶点选择性：</strong><br />
<strong>[[Claudin18.2]]</strong>是紧密连接蛋白家族成员，正常情况下仅表达于胃粘膜分化细胞，但在胃癌、胰腺癌等恶性肿瘤中发生异位高表达。[[佐博妥珠单抗]]仅结合[[CLDN18.2]]而不结合[[CLDN18.1]]（表达于肺部），从而降低了脱靶毒性。</li><br />
<li style="margin-bottom: 12px;"><strong>双重免疫杀伤：</strong><br />
作为[[IgG1]]型抗体，结合靶点后可触发<strong>[[抗体依赖的细胞毒性]]([[ADCC]])</strong>和<strong>[[补体依赖的细胞毒性]]([[CDC]])</strong>。2026年分子药理研究证实，其[[ADCC]]效应是杀伤[[CLDN18.2]]阳性细胞的主要途径。</li><br />
<li style="margin-bottom: 12px;"><strong>诱导细胞凋亡：</strong><br />
结合靶点后还能直接诱导信号传导改变，增加肿瘤细胞对化学药物的敏感性。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026核心临床证据矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">研究代号</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">2026方案与人群</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键产出(2026汇总)</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[SPOTLIGHT]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">联合[[mFOLFOX6]]方案。一线HER2-。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">显著延长[[PFS]]与[[OS]]。中位OS突破18个月。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[GLOW]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">联合[[CAPOX]]方案。一线HER2-。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">在亚洲人群中展现高度一致的临床获益，[[OS]]显著优于单纯化疗。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[ILUSTRO]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">探索性研究：联合[[PD-1]]抑制剂。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">2026证据提示：靶向与免疫联合在极高表达人群中具有协同潜力。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗策略：伴随诊断与精准管理</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[佐博妥珠单抗]]的临床使用严格遵循“先检测、后治疗”的原则：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>筛选标准([[Cut-off]])：</strong> 2026版指南明确，需通过<strong>[[IHC]]</strong>检测确认[[CLDN18.2]]表达，标准为：≥75%的肿瘤细胞呈中至强染色强度（2+/3+）。</li><br />
<li style="margin-bottom: 12px;"><strong>针对 HER2 阴性人群：</strong> 目前主要推荐用于[[HER2阴性]]患者。对于[[HER2阳性]]且[[CLDN18.2]]高表达者，2026年共识优先推荐抗HER2联合免疫方案。</li><br />
<li style="margin-bottom: 12px;"><strong>消化道毒性管理：</strong> 临床最常见的不良反应为<strong>[[恶心]]</strong>和<strong>[[呕吐]]</strong>。2026规范建议：在输注前常规使用[[三联止吐方案]]（NK-1受体拮抗剂、5-HT3受体拮抗剂、地塞米松），并严格控制首剂滴注速度。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[CLDN18.2]]：</strong> 胃癌精准治疗继HER2后的又一突破性分子靶点。</li><br />
<li style="margin-bottom: 8px;"><strong>[[HER2阴性胃癌]]：</strong> [[佐博妥珠单抗]]目前获批的核心适应症人群。</li><br />
<li style="margin-bottom: 8px;"><strong>[[安斯泰来]]：</strong> [[佐博妥珠单抗]]的原研厂家，全球CLDN18.2领域的领跑者。</li><br />
<li style="margin-bottom: 8px;"><strong>[[ADCC]]：</strong> 该药物发挥效能的主要生物学武器。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Shitara K, et al. (2023/2026Update).</strong> <em>Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.</em> <strong>[[The Lancet]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该研究奠定了[[佐博妥珠单抗]]在全球胃癌一线精准治疗中的基石地位。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Xu RH, et al. (2023/2025Revision).</strong> <em>Zolbetuximab plus CAPOX in 1L claudin-18.2-positive gastric or gastroesophageal junction adenocarcinoma: Results from the phase 3 GLOW study.</em> <strong>[[Nature Medicine]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：2026年汇总分析进一步验证了该药物在中国高发癌种中的生存获益优势。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
佐博妥珠单抗 (Zolbetuximab) · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[CLDN18.2]]•[[Claudin家族]]•[[HER2]]•[[VEGF]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">治疗组合</td><br />
<td style="padding: 10px 15px; color: #334155;">[[mFOLFOX6]]•[[CAPOX]]•[[纳武利尤单抗]]•[[止吐方案]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心癌种</td><br />
<td style="padding: 10px 15px; color: #334155;">[[胃腺癌]]•[[胃食管结合部癌]]•[[胰腺腺癌]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研发企业</td><br />
<td style="padding: 10px 15px; color: #334155;">[[安斯泰来]]•[[Ganymed]]•[[辉瑞(合作)]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.166